Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial11

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial8

Views

Views
November 20231
December 20230
January 20242
February 20240
March 20241
April 20241
May 20243
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Colombia1
 

Top cities views

Views
Chicago2
Boardman1
Fort Worth1
Montería1
Newburgh1